Клиническое значение и тактика коррекции анемического синдрома у пациентов с диабетической нефропатией
Диссертация
Изучен вклад различных факторов в развитие анемии у пациентов с ранними стадиями диабетической нефропатии. Определены клинические особенности и лабораторные сдвиги, характерные для больных с анемией на фоне диабетического поражения почек. Проведён сравнительный анализ причин и характера гематологических нарушений при различных стадиях ХБП. Впервые выявлены корреляции между уровнем гемоглобина… Читать ещё >
Содержание
- СПИСОК СОКРАЩЕНИЙ
- Глава 1. ОБЗОР ЛИТЕРАТУРЫ
- 1. 1. Определение и распространённость анемии при диабетической нефропатии
- 1. 2. Механизмы развития анемии при сахарном диабете
- 1. 3. Клиническое значение анемического синдрома у пациентов с диабетической нефропатией
- 1. 4. Общая характеристика лекарственных средств, стимулирующих эритропоэз
- 1. 5. Эффективность и безопасность применения средств, стимулирующих эритропоэз, у пациентов с диабетической нефропатией
- 1. 6. Современные подходы к коррекции анемии у пациентов с диабетической нефропатией
Список литературы
- Бондарь И. А., Климентов В. В., Надеев А. П. Мочевая экскреция провоспалительных цитокинов и трансформирующего фактора роста Р на ранних стадиях диабетической нефропатии // Тер. архив. 2008. — Т. 80, № 1. — С. 52−56.
- Бондарь Т. П., Козинец Г. И. Лабораторно-клиническая диагностика сахарного диабета и его осложнений. М.: ООО «Медицинское информационное агентство», 2003. — 88 с.
- Волкова Н. И., Антоненко М. И. Спорные вопросы диабетической нефропатии (часть I) // Клин, нефрология. 2011. — № 3. — С. 75−78.
- Гуревич К. Я., Гуревич А. К. Анемия при хронической болезни почек. -М.: МДВ, 2010. 88 с.
- Дедов И. И., Шестакова М. В. Сахарный диабет: руководство для врачей. М.: Универсум Паблишинг, 2003. — 456 с.
- Демидова Т. Ю. Сосудистые осложнения сахарного диабета 2 типа за гранью гликемического контроля // Сахарный диабет. 2010. — № 3. -С. 111−116.
- Добронравов В. А., Смирнов А. В., Безруких А. М. Анемия и преддиализные стадии хронической болезни почек: клиническое значение, распространенность и факторы риска // Нефрология. 2006. -Т. 10, № 3.- С. 7−13.
- Ермоленко В. М., Батэрдэнэ С. Активатор рецепторов эритропоэтина длительного действия в лечении анемии у больных с хронической болезнью почек // Клиницист. 2008. — № 4. — С. 50−56.
- Захаров Ю. М. Цитопротекторные функции эритропоэтина // Клин, нефрология. 2009. — № 1. — С. 16−21.
- Куфелкина Т. Ю., ВалееваФ. В. Анемия у больных сахарным диабетом 1 типа // Сахарный диабет. 2010. — № 4. — С. 49−53.
- З.Ларина В. Н., Барт Б. Я., Балабанова Э. Л. Анемический синдром у больных с хронической сердечной недостаточностью // Российский кардиологический журнал. -2010.-№ 3.-С. 34−40.
- Мартынов С. А., Шестакова М. В., Ильин А. В. Эритропоэтин: роль в развитии анемии у больных сахарным диабетом // Нефрол. диал. 2007. -Т. 9, № 3. — С. 336−337.
- Милованов Ю. С., Милованова С. Ю. Анемия при диабетической нефропатии // Лечащий врач. 2008. — № 3. — С. 20−24.
- Румянцев А. Г., Морщакова Е. Д., Павлов А. Д. Эритропоэтин: биологические свойства, возрастная регуляция эритропоэза, клиническое применение. М.: ГЭОТАР-МЕД, 2002. — 400 с.
- Смирнов А. В., Добронравов В. А., Каюков И. Г. Кардио-ренальный континуум: патогенетические основы превентивной нефрологии // Нефрология. 2005. — Т. 9, № 3. — С. 7−15.
- Сунцов Ю. И., Маслова О. В., Казаков И. В. Результаты оценки лечебно-диагностической помощи больным сахарным диабетом по данным проспективных исследований // Сахарный диабет. 2010. — № 3. — С. 2124.
- Хантакова Е. А., Хамнуева Л. Ю., Орлова Г. М. Анемический синдром у больных с сахарным диабетом 1 типа // Сибирский медицинский журнал. 2010. — Т. 94, № 3. — С. 5−8.
- Человеческий рекомбинантный эритропоэтин (Эпокрин) в лечении анемии (Практическое руководство) / под ред. К. Я. Гуревича. СПб.: ИКФ «Фолиант», 2001. — 80 с.
- Чернов В. М., Тарасова В. С., Румянцев А. Г. Анемия в практике терапевта и принципы её коррекции // Лечебное дело. 2011. — № 1. -С. 81−89.
- Шестакова М. В., Дедов И. И. Сахарный диабет и хроническая болезнь почек. М.: ООО «Медицинское информационное агентство», 2009. -482 с.
- Шестакова М. В., Кошель Л. В., Вагодин В. А. и соавт. Факторы риска прогрессирования диабетической нефропатии у больных с длительным течением сахарного диабета по данным ретроспективного анализа // Тер. архив. 2006. — Т. 78, № 5. — С. 34−39.
- Шестакова М. В., Мартынов С. А., ИльинА. В. и соавт. Анемия при диабетической нефропатии: распространённость, клинические и патогенетические аспекты // Тер. архив. 2008. — Т. 80, № 6. — С. 41−47.
- Шестакова М. В., Шамхалова М. Ш., Ярек-Мартынова И. Я. и соавт. Сахарный диабет и хроническая болезнь почек: достижения, нерешенные проблемы и перспективы лечения // Сахарный диабет. 2011. — № 1. -С. 81−88.
- Шило В. Ю. Новый эритропоэз-стимулирующий препарат Аранесп (дарбэпоэтин альфа) в коррекции анемии почечного генеза // Нефрол. диал. 2007. — Т. 9, № 3. — С. 216−223.
- Шило В. Ю. Перспективы лечения анемии у больных хронической почечной недостаточностью // Клиницист. 2006. — № 4. — С. 4−12.
- Шило В. Ю., Денисов А. Ю. Диагностика и лечение нефрогенной анемии у больных на программном гемодиализе: многолетний опыт применения эпоэтина бета // Клиницист. 2006. — № 2. — С. 47−53.
- Шишкин А. Н. Лечение диабетической нефропатии на стадии почечной недостаточности // Новые Санкт-Петербургские врачебные ведомости. -2008. -№ 1.-С. 75−81.
- Шишкин А. Н. Факторы роста и гломерулосклероз при диабетической нефропатии // Нефрология. 2005. — Т. 9, № 4. — С. 104−107.
- Шишкин А. Н., Гуляев А. Н., Ферман Р. С. и соавт. Инфекция Helicobacter pylori при терминальной стадии хронической болезни почек // Нефрология. 2007. — Т. 11, № 4. — С. 59−64.
- Abu-Alfa А.К., CruzD., Perazella М.А. etal. АСЕ inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients // Am. J. Kidney Dis. 2000. — Vol. 35. — P. 1076−1082.
- Adetunji O. R., Mani H., Olujohungbe A. et al. «Microalbuminuric anaemia» — The relationship between haemoglobin levels and albuminuria in diabetes // Diabetes Res. Clin. Pract. 2009. — Vol. 85. — P. 179−182.
- Agarwal N., Prchal J. T. Anemia of chronic disease (Anemia of Inflammation) // Acta Haematol. 2009. — Vol. 122. — P. 103−108.
- Akimoto Т., KuzanoE., FujitaN. etal. Erythropoietin modulates angiotensin II- or noradrenaline-induced Ca2+ mobilization in cultured rat vascular smooth-muscle cells // Nephrol. Dial. Transplant. 2001. — Vol. 16. — P. 491−499.
- Alaveras A. E. G., Thomas S. M., Sagriotis A. et al. Promoters of progression of diabetic nephropathy: The relative roles of blood glucose and blood pressure control // Nephrol. Dial. Transplant. 1997. — Vol. 12, Suppl. 2. — P. 71−74.
- Alicic R. Z., Tuttle K. R. Management of the Diabetic Patient with Advanced Chronic Kidney Disease // Semin. Dial. 2010. — Vol. 23. — P. 140−147.
- Almoznino-Sarafian D., Shteinshnaider M., Tzurl. et al. Anemia in diabetic patients at an internal medicine ward: Clinical correlates and prognostic significance // Eur. J. Int. Med. 2010. — Vol. 21. — P. 91−96.
- Alonso N., Soldevila В., Sanmarti A. et al. Regulatory T cells in diabetes and gastritis // Autoimmun. Rev. 2009. — Vol. 8. — P. 659−662.
- Annese V., Bassotti G., Caruso N. et al. Gastrointestinal motor dysfunction, symptoms, and neuropathy in noninsulin-dependent (Type 2) diabetes mellitus // J. Clin. Gastroenterol. 1999. — Vol. 29. — P. 171−177.
- Astor В. C., CoreshJ., Heiss G. et al. Kidney function and anemia as risk factors for coronary heart disease and mortality: The Atherosclerosis Risk in Communities (ARIC) Study // Am. Heart J. 2006. — Vol. 151. — P. 492−500.
- Astor B.C., Munter P., Levin A. et al. Association of kidney fuction with anemia: the Third National Health and nutritional Examination Survey (19 881 994) // Arch. Int. Med. 2002. — Vol. 162. — P. 1401−1408.
- Ataseven H., DemirM., GenR. Effect of sequential treatment as a first line therapy for helicobacter pylori eradication in patients with diabetes mellitus // South. Med. J. 2010. — Vol. 103. — P. 988−992.
- Bamgbola O. F., Kaskel F. J., Coco M. Analyses of age, gender and other risk factors of erythropoietin resistance in pediatric and adult dialysis cohorts // Pediatr. Nephrol. 2009. — Vol. 24. — P. 571−579.
- Bareford D., Jennings P. E., Stone P. C. et al. Effects of hyperglycaemia and sorbitol accumulation on erythrocyte deformability in diabetes mellitus // J. Clin. Pathol. 1986. — Vol. 39. — P. 722−727.
- Bartesaghi S., Marinovich M., Corsini E. et al. Erythropoietin: A Novel Neuroprotective Cytokine // Neurotoxicology. 2005. — Vol. 26. — P. 923−928.
- Besarab A. What are Common Misconceptions in Dialysis Patient Care? // Semin. Dial. 2011. — Vol. 24. — P. 408−503.
- Beg M., Khan A. R., Katyal P. et al. Erythropoietin response to anaemia in type 2 diabetic nephropathy with varying degrees of renal dysfunction // Diabetes & Metabolic Syndrome. 2008. — Vol. 2. — P. 266−272.
- Bink H., Hondelmann D., Steil H. et al. PTH as a trigger for EPO resistance? // XLVII ERA-EDTA Congress. Munich, Germany. — 2010. — Sa512.
- Bosman D. R., Winkler A. S., Marsden J. T. et al. Anaemia associated with erythropoietin deficiency occurs early in diabetic nephropathy // Diabetes Res. Clin. Pract. 2000. — Vol. 50, Suppl. 1. — P. 265.
- Bouattar T., Ahid S., Benasila S. et al. The factors for progression of the diabetic nephropathy: management and evolution // Nephrol. Ther. 2009. -Vol. 5.-P. 181−187.
- Boyle J. J., Weissberg P. L., Bennett M. R. Tumor necrosis factor-alpha promotes macrophage-induced vascular smooth muscle cell apoptosis by directand autocrine mechanisms // Arterioscler. Thromb. Vase. Biol. 2003. -Vol. 23.-P. 1553−1558.
- Brancaccio D., Cozzolino M., Gallieni M. Hyperparathyroidism and Anemia in Uremic Subjects: A Combined Therapeutic Approach // J. Am. Soc. Nephrol. -2004.-Vol. 15, Suppl. l.-P. S21-S24.
- Brown J. N., Kemp D. W., Brice K. R. Class effect of erythropoietin therapy on hemoglobin A (lc) in a patient with diabetes mellitus and chronic kidney disease not undergoing hemodialysis // Pharmacotherapy. 2009. — Vol. 29. -P. 468−472.
- Buck I., Morceau F., Grigorakaki C. et al. Linking anemia to inflammation and cancer: The crucial role of TNF-a // Biochem. Pharmacol. 2009. — Vol. 77. -P. 1572−1579.
- Cai Z., Semenza G. L. Extra-Hematopoietic Action of Erythropoietin /,/ Textbook of Nephro-Endocrinology / Eds. A. K. Singh, G. H. Williams. 1st ed. Boston: Academic Press, 2009. — P. 27−33.
- Chang Y.-K., Choi D. E., NaK.-R. etal. Erythropoietin Attenuates Renal Injury in an Experimental Model of Rat Unilateral Ureteral Obstruction via Anti-Inflammatory and Anti-Apoptotic effects // J. Urol. 2009. — Vol. 181. -P. 1434−1443.
- Chaturvedi N. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria // Lancet. 1997. — Vol. 349. — P. 1787−1792.
- Conway B., Fried L., Orchard T. Hemoglobin and overt nephropathy complications in type 1 diabetes // Ann. Epidemiol. 2008. — Vol. 18. -P. 147−155.
- Cooij M. A., Groenendaal F., Kavelaars A. et al. Neuroprotective properties and mechanisms of erythropoietin in 'in vitro' and 'in vivo' experimental models for hypoxia/ischemia // Brain Res. Rev. 2008. — Vol. 59. — P. 22−33.
- Cotroneo P., Grattagliano A., Rapaccini G. L. et al. Gastric emptying rate and hormonal response in type II diabetics // Diabetes Res. 1991. — Vol. 17. -P. 99−104.
- Cotroneo P., Ricerca B. M., Todaro L. Blunted erythropoietin response to anemia in patients with Type 1 diabetes // Diabetes Metab. Res. Rev. 2000. -Vol. 16.-P. 172−176.
- Courtney A. E., Maxwell A P. Critiques of clinical guidelines in nephrology: Anaemia // Nephron Clin. Pract. 2008. — Vol. 110. — P. cl 15-cl25.
- Coyne D. W. The future of intravenous iron in nephrology // NDT Plus. -2011. Vol. 4, Suppl. 1. — P. i6-i9.
- Craig K. J., Williams J. D., Riley S. G. et al. Anemia and Diabetes in the Absence of Nephropathy // Diabetes Care. 2005. — Vol. 28. — P. 1118−1123.
- Dandona P., Aljada A., Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes // Trends Immunol. 2004. — Vol. 25. -P. 4−7.
- Dandona P., Chaudhuri A. Anti-inflammatory and antiatherogenic effects of insulin // Insulin. 2006. — Vol. 1, Suppl. 1. — P. SI 1-S17.
- Del Fabbro P., Luthi J.-C., Carrera E. et al. Anemia and chronic kidney disease are potential risk factors for mortality in stroke patients: A historic cohort study // BMC Nephrol. 2010. — Vol. 11, № 27. — P. 1−10.
- De Francisco A. L. M., Pinera C. Anemia trials in CKD and clinical practice: Refining the approach to erythropoiesis-stimulating agents // Contrib. Nephrol. 2011. — Vol. 171. — P. 248−254.
- Del Vecchio L., Locatelli F. Erythropoietin and iron therapy in patients with renal failure // Transfus. Altern. Transfus. Med. 2010. — Vol. 11. — P. 20−29.
- Demir M., GogturkH. S., OzturkN. A. et al. Helicobacter pylori prevalence in diabetes mellitus patients with dyspeptic symptoms and its relationship to glycemic control and late complications // Dig. Dis. Sci. 2008. — Vol. 53. -P. 2646−2649.
- Dikow R., Schwenger V., Schomig M. et al. How should we manage anaemia in patients with diabetes? // Nephrol. Dial. Transplant. 2002. Vol. 17, Suppl. l.-P. 67−72.
- Driieke T. B., Locatelli F., Clyne N. et al. Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia // N. Engl. J. Med. -2006. Vol. 355. — P. 2071−2084.
- Dulaney .J. T., Hatch Jr. F. E. Youns J. et al. Effect of amines on erythropoietin-stimulated heme synthesis in fetal mouse liver cells // Life Sci. -1985. Vol. 36. — P. 1633−1642.
- Eckardt K.-U. Erythropoietin and microvascular diabetic complications // Nephrol. Dial. Transplant. 2009. — Vol. 24. — P. 388−390.
- Eckardt K.-U. Managing a fateful alliance: Anaemia and cardiovascular outcomes // Nephrol. Dial. Transplant. 2005. — Vol. 20, Suppl. 6. — P. 16−20.
- Eckardt K.-U. Pathophysiology of renal anemia // Clin. Nephrol. 2000. Vol. 53, Suppl. l.-P. S2-S8.
- Eisenstaedt R., Penninx B., Woodman R. C. Anemia in the elderly: Current understanding and emerging concepts // Blood Rev. 2006. — Vol. 20. -P. 213−226.
- Elliott S., PhamE., Macdougall I. C. Erythropoietins: A common mechanism of action // Exp. Hematol. 2008. — Vol. 36. — P. 1573−1584.
- Eschbach J. W. Iron requirements in erythropoietin therapy// Best Pract. Res. Clin. Haematol.-2005.-Vol. 18.-P. 347−361.
- Fine L. G., Norman J. T. Chronic hypoxia as a mechanism of progression of chronic kidney diseases: From hypothesis to novel therapeutics // Kidney Int. -2008. Vol. 74. — P. 867−872.
- Fuste B., Seradell M., Escolar G. et al. Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro // Thromb. Haemost. 2002. — Vol. 88. — P. 678 685.
- Gasbarrini A., Ojetti V., PitoccoD. et al. Insulin-dependent diabetes mellitus affects eradication rate of Helicobacter pylori infection // Eur. J. Gastroenterol. Hepatol. 1999.-Vol. 11. -P 713−716.
- Gene S., Koroglu T. F., Gene K. Erythropoietin and the nervous system // Brain Res. 2004. — Vol. 1000.-P. 19−31.
- Genuth S. G. HbAlc for diagnosis: Progress or the wrong direction? // World Diabetes Congress. Dubai, UAE. — 2011. — P. 56.
- Goldberg R. B. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications // J. Clin. Endocrinol. Metab. 2009. — Vol. 94. — P. 3171 -3182.
- Goldsmith D., Covic A. Time to Reconsider Evidence for Anaemia Treatment (TREAT) = Essential Safety Arguments (ESA) // Nephrol. Dial. Transplant. -2010. Vol. 25. — P. 1734−1737.
- Herzog C. A., Muster H. A., Li S., Collins A. J. Impact of congestive heart failure, chronic kidney disease, and anemia on survival in the Medicare population // J. Card. Fail. 2004. — Vol. 10. — P. 467−472.
- Hillege H. L., Girbes A. R. J., De Kam P. J. et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure // Circulation. 2000. — Vol. 102. — P. 203−210.
- Hirase N., Yanase T., Mu Y.-M. et al. Thiazolidinedione suppresses the expression of erythroid phenotype in erythroleukemia cell line K562 // Leuk. Res. 2000. — Vol. 24. — P. 393−400.
- HirataA., Minamino T., AsanumaH. etal. Erythropoietin Enhances Neovascularization of Ischemic Myocardium and Improves Left Ventricular Dysfunction After Myocardial Infarction in Dogs // J. Am. Coll. Cardiol. -2006.-Vol. 48.-P. 176−184.
- Hoeldtke R. D., Streeten D. Treatment of orthostatic hypotension with erythropoietin // N. Engl. J. Med. 1993. — Vol. 329. — P. 611−615.
- Horowitz M., O’DonovanD., Jones K. L. et al. Gastric emptying in diabetes: Clinical significance and treatment // Diabet. Med. 2002. — Vol. 19. — P. 177 194.
- International Diabetes Federation. Diabetes The Policy Puzzle: Is Europe Making Progress? 3rd ed. Brussels, 2011. — 159 p. th
- International Diabetes Federation. IDF Diabetes Atlas. 5 ed. Brussels, 2011.- 143 p.
- Jacobsen P., Tarnow L., Carstensen B. et al. Genetic Variation in the Renin-Angiotensin System and Progression of Diabetic Nephropathy // J. Am. Soc. Nephrol. 2003. — Vol. 14. — P. 2843−2850.
- Jelkmann W. Erythropoietin after a century of research: Younger that ever // Eur. J. Haematol. 2007. — Vol. 78. — P. 183−205.
- Johnson D. W., Forman C., VeseyD. A. Novel renoprotective actions of erythropoietin: New uses of an old hormone // Nephrology. 2006. -Vol. 11.-P. 306−312.
- Johnson D. W., Pollock C. A., Macdougall I. C. Erythropoiesis-stimulating agent hyporesponsiveness (Review Article) // Nephrology. 2007. — Vol. 12. -P. 321−330.
- Jones S., Jones S., Phillips A. O. Regulation of renal proximal tubular epithelial cell hyaluronan generation: Implications for diabetic nephropathy // Kidney Int.-2001.-Vol. 59.-P. 1739−1749.
- Joss N., Patel R., Paterson K. et al. Anaemia is common and predicts mortality in diabetic nephropathy // QJM. 2007. — Vol. 100. — P. 641−647.
- Kahraman S., YilmazR., KirkpanturA. et al. Impact of rhEPO therapy initiation on soluble adhesion molecule levels in haemodialysis patients // Nephrology. 2005. — Vol. 10. — P. 64−69.
- Kainz A., Mayer B., KramarR., OberbauerR. Association of ESA hypo-responsiveness and haemoglobin variability with mortality in haemodialysis patients // Nephrol. Dial. Transplant. 2010. — Vol. 25. — P. 3701−3706.
- KaluzS., KaluzovaM., Stanbridge E. J. Regulation of gene expression by hypoxia: Integration of the HIF-transduced hypoxic signal at the hypoxia-responsive element // Clin. Chim. Acta. 2008. — Vol. 395. — P. 6−13.
- Kaufman J. S. Subcutaneous erythropoietin therapy: efficacy and economic implications //Am. J. Kidney Dis. 1998. — Vol. 32, Suppl. 4. — P. S147-S151.
- Kaul K., Hodgkinson A., TarrJ. M. Is inflammation a common retinal-renal-nerve pathogenic link in diabetes?// Curr. Diab. Rev. 2010. — Vol.6. -P. 294−303.
- Kazory A., Ross E. A. Anemia: The Point of Convergence or Divergence for Kidney Disease and Heart Failure? // J. Am. Coll. Cardiol. 2009. — Vol. 53. -P. 639−647.
- Kessler M. Erythropoietin and erythropoiesis in renal transplantation // Nephrol. Dial. Transplant. 1995. — Vol. 10. — P. 114−116.
- Khoshdel A., Carney S., Gillies A. et al. Potential roles of erythropoietin in the management of anaemia and other complications diabetes // Diabetes Obes. Metab. 2008. — Vol. 10. — P. 1−9.
- Kim M. K., Baek K. H., Lim D. J. et al. Erythropoietin response to anemia and its association with autonomic neuropathy in type 2 diabetic patients without advanced renal failure // J. Diabetes Complications. 2010. — Vol. 24. — P. 9095.
- Kleijn L., Boer R. A., Voors A. A. Should erythropoietin treatment in chronic heart failure be haemoglobin targeted? // Eur. J. Heart Fail. 2010. — Vol. 12. -P. 215−216.
- Kung C.-M., Tseng Z.-L., WangH.-L. Erythrocyte fragility increases with level of glycosylated hemoglobin in type 2 diabetic patients // Clin. Hemorheol. Microcirc. 2009. — Vol. 43. — P. 345−351.
- Lankhorst C. E., Wish J. B. Anemia in renal disease: Diagnosis and management // Blood Rev. 2010. — Vol. 24. — P. 39−47.
- LindL. Circulating markers of inflammation and atherosclerosis// Atherosclerosis. 2003. — Vol. 169. — P. 203−214.
- Locatelli F. Iron treatment and the TREAT trial // NDT Plus. 2011. — Vol. 4, Suppl. l.-P. 3−5.
- Locatelli F., AljamaP., BaranyP. et al. Revised European best practice guidelines for the management of anemia in patients with chronic renal failure // Nephrol. Dial. Transplant. 2004. — Vol. 19, Suppl. 2. — P. 1−47.
- Locatelli F., Andrulli S., Memoli B. et al. Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients // Nephrol. Dial. Transplant. 2006. — Vol. 21. — P. 991−998.
- Locatelli F., Del VecchioL. Erythropoietic response to erythropoiesis-stimulating agents and outcome: should we give up the haemoglobin target approach? // Nephrol. Dial. Transplant. 2011. — Vol. 26. — P. 2069−2071.
- Locatelli F., Del Vecchio L. Hematide for the treatment of chronic kidney disease-related anemia // Exp. Rev. Hematol. 2009. — Vol. 2. — P. 377−383.
- Ludwig H., Strasser K. Symptomatology of anemia // Seminars in Oncology. -2001. Vol. 28, Suppl. 8. — P. 7−14.
- Lykissas M. G., Sakellariou E., VekrisM. D. et al. Axonal regeneration stimulated by erythropoietin: An experimental study in rats // J. Neurosci. Methods. 2007. — Vol. 164. — P. 107−115.
- Macdougall I. C. Anaemia and chronic renal failure // Medicine. 2011. -Vol. 39.-P. 425−428.
- Macdougall I. C. Quality of life and anemia: The nephrology experience// Semin. Oncol. 1998. — Vol. 25, Suppl. 7. — P. 39−42.
- Macdougall I. C. Role of uremic toxins in exacerbating anemia in renal failure // Kidney Int. 2001. — Vol. 59. — P. S67-S72.
- Magri C. J., Fava S. The role of tubular injury in diabetic nephropathy // Eur. J. Intern. Med. 2009. — Vol. 20. — P. 551−555.
- Malyszko Jac., Malyszko Jol., Kozminski P. et al. Hepcidin and functional iron deficiency in hemodialysed patients // XLVII ERA-EDTA Congress. -Munich, Germany. 2010. — Sa532.
- Marollo M., Latella G., Melideo D. et al. Increased prevalence of Helicobacter pylori in patients with diabetes mellitus // Dig. Liver Dis. 2001. — Vol. 33. -P. 21−29.
- Marsden P. A. Treatment of Anemia in Chronic Kidney Disease — Strategies Based on Evidence // N. Engl. J. Med. 2009. — Vol. 361. — P. 2089−2090.
- McFarlane P. A., HilmerM. P., DacourisN. A change from subcutaneous to intravenous erythropoietin increases the cost of anemia therapy // Nephron Clin. Pract. 2007. — Vol. 107. — P. C90-C96.
- McGill J. B., Bell D. S. H. Anemia and the role of erythropoietin in diabetes // J. Diabetes Complications. 2006. — Vol. 20. — P. 262−272.
- MehdiU., TotoR. D. Anemia, Diabetes, and Chronic Kidney // Diabetes Care. 2009. — Vol. 32. — P. 1320−1326.
- MiuraT., Miki T., NishiharaM. etal. Molecular mechanisms of cardiomyocyte protection against ischemia/reperfusion injury by erythropoietin (EPO) receptor activation // J. Mol. Cell. Cardiol. 2006. — Vol. 41. — P. 10 431 044.
- Mohanram A., Zhang Z., Shahinfar S. et al. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy // Kidney Int. -2004.-Vol. 66.-P. 1131−1138.
- Nagarajan S., MansfieldE., Hsieh S. etal. Transplant reno-vascular stenoses associated with early erythropoietin use // Clin. Transplant. 2007. -Vol. 21.-P. 597−608.
- Nangaku M., EckardtK. Hypoxia and the HIF system in kidney disease // J. Molec. Med. 2007. — Vol. 85. — P. 1325−1330.
- National Kidney Foundation: K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia of chronic kidney disease // Am. J. Kidney Dis. 2006. — Vol. 46, Suppl. 3. — P. SI-SI45.
- Navarro-Gonzalez J. F., Mora-Fernandez C. The Role of Inflammatory Cytokines in Diabetic Nephropathy // J. Am. Soc. Nephrol. 2008. -Vol. 19.-P. 433−442.
- Navarro-Gonzalez J. F., Mora-Fernandez C. The role of TNF-a in diabetic nephropathy: Pathogenic and therapeutic implications // Cytokine Growth Factor Rev. 2006. — Vol. 17. — P. 441−450.
- Navarro-Gonzalez J. F., Mora-Fernandez C., De FuentesM. M. et al. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy // Nat. Rev. Nephrol. 2011. — Vol. 7. — P. 327−340.
- Navarro-Gonzalez J. F., Muros M., Mora-Fernandez C et al. Pentoxifylline for Renoprotection in Diabetic Nephropathy: The PREDIAN study. Rationale and basal results // J. Diabetes Complications. 2011. — Vol. 25. — P. 314−319.
- Norman J. T., Orphanides C., Garcia P., Fine L. G. Hypoxia-induced changes in extracellular matrix metabolism in renal cells // Exp. Nephrol. 1999. -Vol. 7. — P. 463−469.
- Nosadini R., Tonolo G. Relationship between Blood Glucose Control, Pathogenesis and Progression of Diabetic Nephropathy // J. Am. Soc. Nephrol. 2004. — Vol. 15, Suppl. l.-P. S1-S5.
- Nowicki M., KokotF., KokotM. et al. Renal clearance of endogenous erythropoietin in patients with proteinuria // Int. Urol. Nephrol. 1994. -Vol. 26.-P. 691−699.
- O’Hare P., Bilous R., Mitchel T. et al. Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: Results of a randomized controlled trial// Diabetes Care. 2000. — Vol.23. — P. 18 231 829.
- O’Leary F., Samman S. Vitamin B12 in health and disease // Nutrients. -2010.-Vol. 2.-P. 299−316.
- Pagourelias E. D., Koumaras C., Kakafika A. I. Cardiorenal anemia syndrome: Do erythropoietin and iron therapy have a place in the treatment of heart failure? // Angiology. 2009. — Vol. 60. — P. 74−81.
- Pallet N., BouvierN., Legendre C. etal. Antiapoptotic properties of recombinant human erythropoietin protects against tubular cyclosporine toxicity // Pharmacol. Res. 2010. — Vol. 61. — P. 71−75.
- Parfrey P. S. Erythropoietin-stimulating Agents in Chronic Kidney Disease: A Response to Hyporesponsiveness // Semin. Dial. 2011. — Vol. 24. — P. 495 497.
- Parving H. H. General management of diabetic nephropathy // World Diabetes Congress. Dubai, UAE. — 2011. — P. 58.
- Perugini M., VareliasA., SadlonT. et al. Hematopoietic growth factor mimetics: From concept to clinic // Cytokine Growth Factor Rev. 2009. -Vol. 20. — P. 87−94.
- Pfeffer M. A., Burdmann E. A., Chen C. Y. et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease // N. Engl. J. Med. 2009. -Vol. 361.-P. 2019−2032.
- Pfeffer M. A., Burdmann E. A., Chen C. Y. et al. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) // Am. J. Kidney Dis. 2009. — Vol. 54. — P. 59−69.
- Philippe M.-F., Benabadji S., Barbot-Trystram L. et al. Pancreatic volume and endocrine and exocrine functions in patients with diabetes // Pancreas. -2011.-Vol. 40.-P. 359−363.
- Piccoli A., Pastori G., PerobonE. et al. Anti-renin-angiotensin-system drugs and development of anemia in chronic kidney disease // J. Nephrol. 2005. -Vol. 18.-P. 585−591.
- Pommelet C. L., Moullec N. L., Zunic P. Diabetic ketoacidosis revealing glucose-6-phosphate dehydrogenase deficiency: Description of an adult case // Diabetes Metab. 2006. — Vol. 32. — P. 636−637.
- Popovsky M. A., Ransil B. J. Long-term impact of recombinant human erythropoietin on transfusion support in patients with chronic renal failure // Immunohematology. 1996. — Vol. 12. — P. 1−3.
- Quin C., XiaoY., Zhong Q. etal. Anti-inflammatory effect of erythropoietin pretreatment on cardiomyocytes with hypoxia/reoxygenation injury and the possible mechanism // Chin. J. Traumatol. 2008. — Vol. 11. — P. 352−358.
- Radeke H. H, Meier B., TopleyN. et al. Interleukin 1-a and tumor necrosis factor-a induce oxygen radical production in mesangial cells // Kidney Int. -1990.-Vol. 37.-P. 767−775.
- Raj D. S. C. Role of Interleukin-6 in the Anemia of Chronic Disease // Semin. Arthritis Rheum. 2009. — Vol. 38. — P. 382−388.
- Righetti M., Ferrario G., Serbeloni P. et al. Severe hyperhomocysteinemia improves erythropoiesis stimulating agent resistivity index in hemodialysis patients // XLVII ERA-EDTA Congress. Munich, Germany. — 2010. -Sa543.
- Ritz E., Haxsen V. Diabetic nephropathy and anaemia // Eur. J. Clin. Invest. -2005. Vol. 35, Suppl. 3. — P. 66−74.
- Robinson B. M., Joffe M. M., Berns J. S. Anemia and mortality in hemodialysis patients: Accounting for morbidity and treatment variables updated over time // Kidney Int. 2005. — Vol. 68. — P. 2323−2330.
- Rodgers K. E., Xiong S., Steer R., DiZeregaG. S. Effect of angiotensin II on hematopoietic progenitor cell proliferation // Stem Cells. 2000. — Vol. 18. -P. 287−294.
- Roob J. M., Khoschsosur G., TiranA. et al. Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis // J. Am. Soc. Nephrol. 2000. — Vol. 11. — P. 539−549.
- Roszyk L., Faye B., Sapin V. et al. Glycated haemoglobin (HbAlc): today and tomorrow // Ann. Endocrinol. (Paris). 2007. — Vol. 68. — P. 357−365.
- Ruifrok W.-P. T., Boer R. A., Westenbrink B. D. etal. Erythropoietin in cardiac disease: New features of an old drug // Eur. J. Pharmacol. 2008. -Vol. 585.-P. 270−277.
- Sahin M., Tutuncu N. B., Ertugrul D. Effects of metformin or rosiglitazone on serum concentrations of homocysteine, folate, and vitamin B12 in patients with type 2 diabetes mellitus // J. Diabetes Complications. 2007. — Vol.21. -P. 118−123.
- Saito T., Tojo K., Morimoto A. et al. Normocytic normochromic anemia due to autonomic neuropathy in type 2 diabetic patients without severe nephropathy. A possible role of microangiopathy // Diabetes Res. Clin. Pract. 2005. Vol. 70. — P. 239−247.
- Saito T., Tojo K., Nishimura R. et al. Coefficient of variation of R-R intervals in electrocardiogram is a sensitive marker of anemia induced by autonomic neuropathy in type 1 diabetes // Diabetes Res. Clin. Pract. 2007. — Vol. 78. -P. 60−64.
- Sanchez-Roman S., Ostrovsky-Solis F., Morales-Buenrostro L. E. et al. Neurocognitive Profile of an Adult Sample With Chronic Kidney Disease // J. Int. Neuropsyhol. Soc. 2011. — Vol. 17. — P. 80−90.
- Sasso F. C., De Nicola L., CarbonaraO. Cardiovascular risk factors and disease management in type 2 diabetic patients with diabetic nephropathy // Diabetes Care. 2006. — Vol. 29. — P. 498−503.
- Savino C., Pedotti R., Baggi F. et al. Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis // J. Neuroimmunol. 2006. — Vol. 172. — P. 27−37.
- Sawaki H., Terasaki J., Fujita A. A renoprotective effect of low dose losartan in patients with type 2 diabetes // Diabetes Res. Clin. Pract. 2008. -Vol. 79.-P. 86−90.
- Schvarcz E., Palmer M., Aman J. et al. Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin-dependent diabetes mellitus // Gastroenterology. 1997. — Vol. 113. — P. 60−66.
- Scrutinio D., Passatino A., SantoroD., Catanzaro R. The cardiorenal anaemia syndrome in systolic heart failure: Prevalence, clinical correlates, and long term survival // Eur. J. Heart Fail. 2011. — Vol. 13. — P. 61−67.
- Segerer S., Nelson P. J., Schlondorff D. Chemokines, Chemokine Receptors, and Renal Disease: From Basic Science to Pathophysiological and Therapeutic Studies // J. Am. Soc. Nephrol. 2000. — Vol. 11. — P. 152−176.
- SekiguchiN., Inoguchi T., Kobayashi K. etal. Erythropoietin attenuated high glucose-induced apoptosis in cultured human aortic endothelial cells // Biochem. Biophys. Res. Commun. 2005. — Vol. 34. — P. 218−222.
- Shahbazian H., Ghorbani A., EhsanpourA. et al. Pentoxiphylline in improvement of erythropoietin-resistant anemia in end stage renal disease // XLVII ERA-EDTA Congress. Munich, Germany. — 2010. — Sa529.
- Shu D. H., Ransom T. P. P., O’Connel C. M. et al. Anemia is an independent risk for mortality after acute myocardial infarction in patients with and without diabetes // Cardiovasc. Diabetol. 2006. — Vol. 5, № 8. — P. 1−9.
- Shvidel L., Arcavi L., SiglerE. Symptomatic anemia induced by rosiglitazone // Eur. J. Int. Med. 2007. — Vol. 18. — P. 348.
- Silverberg D., WexlerD., BlumM. The cardio-renal anaemia syndrome: Does it exist? // Nephrol. Dial. Transplant. 2003. — Vol. 18, Suppl. 8. — P. 7−12.
- SilverbergD. S., WexlerD., IainaA., SchwartzD. Anemia, chronic renal disease and chronic heart failure: The cardiorenal anemia syndrome // Transfiis. Altern. Transfus. Med. 2008. — Vol. 10. — P. 189−196.
- Sims M. A., HaslerW. L., CheyW. D. et al. Hyperglycemia inhibits mechanoreceptor-mediated gastrocolonic responses and colonic peristaltic reflexes in healthy humans // Gastroenterology. 1995. — Vol. 108. — P. 350 359.
- Singh A. K. Diabetes, anemia and ckd: Why treat? // Curr. Diab. Rep. -2010.-Vol. 10.-P. 291−296.
- Singh A. K. Hemoglobin control, ESA resistance, and regular low-dose IV iron therapy: A review of the evidence // Semin. Dial. 2009. — Vol. 22. — P. 64−69.
- Singh A. K. Is there a deleterious effect of erythropoietin in end-stage renal disease? // Kidney Int. 2011. — Vol. 80. — P. 569−571.
- Singh A. K. What is causing the mortality in treating the anemia of chronic kidney disease: Erythropoietin dose or hemoglobin level? // Curr. Opin. Nephrol. Hypertens. 2010. — Vol. 19. — P. 420−424.
- Singh A. K., Szczech L., Tang K. L. et al. Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease // N. Engl. J. Med. 2006. — Vol. 355. -P. 2085−2098.
- Siragy H. M., A wad A., AbadirP. et. al. The angiotensin II type 1 receptor mediates renal interstitial content of tumor necrosis factor-a in diabetic rats // Endocrinology. 2003. — Vol. 144. — P. 2229−2233.
- Smith G. L., Lichtman J. H., Bracken M. B. et al. Renal Impairment and Outcomes in Heart Failure: Systematic Review and Meta-Analysis // J. Am. Coll. Cardiol. 2006. — Vol. 47. — P. 1987−1996.
- Solomon S. D., Uno H., Lewis E. F. et al. Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes // N. Engl. J. Med. 2010. -Vol. 363.-P. 1146−1155.
- Spallone V., Maiello M. R., Kurukulasuriya N. et al. Does autonomic neuropathy play a role in erythropoietin regulation in non-proteinuric Type 2 diabetic patients? // Diabet. Med. 2004. — Vol. 21. — P. 1174−1180.
- Stasko J., GalajdaP., IvankovaJ. et al. Soluble P-selectin during a single hemodialysis session in patients with chronic renal failure and erythropoietin treatment // Clin. Appl. Thromb. Hemost. 2007. — Vol. 13. — P. 410−415.
- Stolic R. V., Trajkovic G. Z., Peric V. M. et al. Impact of Metabolic Syndrome and Malnutrition on Mortality in Chronic Hemodialysis Patients // J. Ren. Nutr. 2010. — Vol. 20. — P. 38−43.
- Stoves J., Ingles H., Newstead C. G. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin // Nephrol. Dial. Transplant. 2001. — Vol. 16. — P. 967 974.
- Szapanowska-Wohn A., Kolarzyk E., Chowaniec E. et al. Estimation of intake of zinc, copper and iron in the diet of patients with chronic renal failure treated by hemodialysis // Biol. Trace Elem. Res. 2008. — Vol. 124. — P. 97−102.
- Szlanka B., Borbas B. Hemoglobin variability, treatment difficulty in anaemia management of haemodialysis patients // XLVII ERA-EDTA Congress. -Munich, Germany. 2010. — Su570.
- Tang W. H. W. Anemia in heart failure: Current evidence and challenges // Rev. Cardiovasc. Med. 2007. — Vol. 8. — P. 78−86.
- Tarng D. C., Wei Y. H., Huang T. P. et al. Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia // Kidney Int. 1999. — Vol. 55. — P. 2477−2486.
- Thomas M. C. The High Prevalence of Anemia in Diabetes Is Linked to Functional Erythropoietin Deficiency // Semin. Nephrol. 2006. — Vol. 26. -P. 275−282.
- Thomas M. C., Maclsaac R. J., Tsalamandris C. et al. Anemia in patients with Type 1 diabetes // J. Clin. Endocrinol. Metab. 2004. — Vol. 89. — P. 43 594 363.
- Thomas M. C., Maclsaac R. J., Tsalamandris C. et al. Unrecognized Anemia in Patients With Diabetes: A cross-sectional survey // Diabetes Care. 2003. -Vol. 26.-P. 1164−1169.
- Thomas M. C., Tsalamandris C., Maclsaac R. J. et al. Functional erythropoietin deficiency in patients with Type 2 diabetes and anaemia // Diabet. Med. -2006.-Vol. 23.-P. 502−509.
- Thomas S., RampersadM. Anaemia in diabetes // Acta Diabetol. 2004. -Vol. 41, Suppl. l.-P. S13-S17.
- TobaH., SawaiN., MorishitaM. et al. Chronic treatment with recombinant human erythropoietin exerts renoprotective effects beyond hematopoiesis in streptozotocin-induced diabetic rat // Eur. J. Pharmacol. 2009. — Vol. 612. -P. 106−114.
- TopalM., Sezer S., AcarN.O. Factors affecting hemoglobin variations in hemodialysis patients // XLVII ERA-EDTA Congress. Munich, Germany. -2010. — Sa545.
- Tsagalis G. Renal anemia: A nephrologist’s view // Hippokratia. 2011. -Vol. 15, Suppl. l.-P. 39−43.
- Unger E. F., Thompson A. M., Blank M. J. Erythropoiesis-Stimulating Agents— Time for a reevaluation// N. Engl. J. Med. 2010. — Vol. 362. -P. 189−192.
- Vaziri N. D. Cardiovascular effects of erythropoietin and anemia correction // Curr. Opin. Nephrol, and Hypertens. 2001. — Vol. 10. — P. 633−637.
- Vaziri N. D. Mechanism of erythropoietin-induced hypertension // Am. J. Kidney Dis. 1999. — Vol. 33. — P. 821−828.
- Vaziri N. D., Zhou X. J. Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease // Nephrol. Dial. Transplant. 2009. — Vol. 24. — P. 1082−1088.
- Vinzio S., Andres E., Perrin A. E. et al. Glibenclamide-induced acute haemolytic anaemia revealing a G6PD-deficiency // Diabetes Res. Clin. Pract. 2004. — Vol. 64. — P. 181−183.
- Vlagopoulos P. T., Tighiouart H., Weiner D. E. et al. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: The impact of chronic kidney disease// J. Am. Soc. Nephrol. 2005. — Vol. 16. — P. 34 033 410.
- Vlahakos D. V., Marathias K. P., Madias N. E. The role the renin-angiotensin system in the regulation of erythropoiesis // Am. J. Kidney Dis. 2010. -Vol. 56.-P. 558−565.
- Vogel V., Kramer H. J., Backer A. et al. Effects of Erythropoietin on Endothelin-1 Synthesis and the Cellular Calcium Messenger System in Vascular Endothelial Cells // Am. J. Hypertens. 1997. — Vol. 10. — P. 289 296.
- Wang W., Zhang J. Protective effect of erythropoietin against aristolochic acid-induced apoptosis in renal tubular epithelial cells // Eur. J. Pharmacol, -2008. Vol. 588. — P. 135−140.
- Winearls C. G. Recombinant human erythropoietin: 10 years of clinical experience // Nephrol. Dial. Transplant. 1998. — Vol. 13, Suppl. 2. — P. 3−8.
- Winkler A. S., Marsden J., Chaudhuri K. R. et al. Erythropoietin depletion and anemia in diabetes mellitus // Diabet. Med. 1999. — Vol. 16. — P. 813−819.
- Wolkow P. P., Niewczas M. A., Perkins B. et al. Association of urinary inflammatory markers and renal decline in microalbuminuric type 1 diabetics // J. Am. Soc. Nephrol. 2008. — Vol. 19. — P. 789−797.
- Woodburn K. W., Fan Q., Winslow S. et al. Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model // Exp. Hematol. 2007. -Vol. 35.-P. 1201−1208.
- Worldwide prevalence of anaemia 1993−2005: WHO global database on anaemia / Eds. B. de Benoist, E. McLean, I. Egli, M. Cogswell. Geneva: WHO Press, 2008. — 40 p.
- Wright R. J., Kanagasundaram N. S., Quinton R. et al. Darbepoetin alfa and chronic kidney disease // N. Engl. J. Med. 2010. — Vol. 362. — P. 653−654.
- Yang L., Brozovic S., Xu J. et al. Inflammatory gene expression in OVE26 diabetic kidney during the development of nephropathy // Nephron Exp. Nephrol. 2011. — Vol. 119. — P. e8-e20.
- Yun Y. S., Lee H. C., Song Y. D. Reduced erythropoietin responsiveness to anemia in diabetic patients before a advanced diabetic nephropathy // Diabetes Res. Clin. Pract. 1999. — Vol. 46. — P. 223−229.
- ZakaiN. A., KatzR., Hirsch C. et al. A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: The cardiovascular health study // Arch. Intern. Med. 2005. — Vol. 165. — P. 22 142 220.
- Ziakka S., Zagorianakos A., Koutsovasili A. et al. Efficacy of hemopoietic-stimulating factors in patients undergoing chronic hemodialysis // Ren. Fail. -2011.-Vol. 33.-P. 923−928.